O

    Ocular Therapeutix Inc (OCUL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.49
    +0.13 (+1.25%)

    Market Cap: $2.28B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/40)
    Avg Surprise
    -24.45%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.37 - $-0.30
    5 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate Drift
    90d ago$-0.39-10.1%
    60d ago$-0.39-10.1%
    30d ago$-0.39-10.1%
    7d ago$-0.35+0.0%
    Current$-0.35
    Revenue Consensus
    $14M
    Range$13M - $16M
    11 analysts
    Dec 31, 2026
    EPS Consensus$-0.37
    Range$-0.48 - $-0.12
    4 analysts
    Revenue Consensus
    $13M
    Range$11M - $16M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.37---
    Sep 26EST
    		-$-0.35---
    Jun 26
    		$-0.35$-0.40+12.50%Beat+10.3%
    Mar 26
    		$-0.40$-0.31-29.03%Miss-8.1%
    Dec 25
    		$-0.29$-0.34+14.71%Beat+0.0%
    Sep 25
    		$-0.38$-0.35-8.57%Miss-72.7%
    Jun 25
    		$-0.39$-0.35-11.43%Miss-50.0%
    Mar 25
    		$-0.37$-0.28-32.14%Miss-54.2%
    Dec 24
    		$-0.29$-0.22-31.82%Miss+17.1%
    Sep 24
    		$-0.22$-0.21-4.76%Miss-15.8%
    Jun 24
    		$-0.26$-0.21-23.81%Miss+0.0%
    Mar 24
    		$-0.24$-0.18-33.33%Miss+22.6%
    Dec 23
    		$-0.35$-0.30-16.67%Miss-45.8%
    Sep 23
    		$-0.19$-0.25+24.00%Beat+36.7%
    Jun 23
    		$-0.26$-0.29+10.34%Beat-23.8%
    Mar 23
    		$-0.31$-0.24-29.17%Miss-24.0%
    Dec 22
    		$-0.24$-0.25+4.00%Beat-380.0%
    Sep 22
    		$-0.30$-0.21-42.86%Miss-7.1%
    Jun 22
    		$-0.21$-0.18-16.67%Miss+27.6%
    Mar 22
    		$-0.25$-0.22-13.64%Miss+13.8%
    Dec 21
    		$-0.05N/A+78.26%Beat+95.9%
    Sep 21
    		$-0.28$-0.26-7.69%Miss-47.4%
    Jun 21
    		$-0.29$-0.21-38.10%Miss+54.7%
    Mar 21
    		$-0.29$-0.21-38.10%Miss+29.3%
    Dec 20
    		$-1.21$-0.17-611.76%Miss-128.3%
    Sep 20
    		$-0.19$-0.25+24.00%Beat+57.8%
    Jun 20
    		$-0.64$-0.32-100.00%Miss-12.3%
    Mar 20
    		$-0.41$-0.49+16.33%Beat+14.6%
    Dec 19
    		$-0.53$-0.45-17.78%Miss-26.2%
    Sep 19
    		$-0.45$-0.46+2.17%Beat-18.4%
    Jun 19
    		$-0.57$-0.48-18.75%Miss-54.1%
    Mar 19
    		$-0.48$-0.42-14.29%Miss-20.0%
    Dec 18
    		$-0.42$-0.38-10.53%Miss+4.5%
    Sep 18
    		$-0.38$-0.37-2.70%Miss+29.6%
    Jun 18
    		$-0.37$-0.37+0.00%Beat+42.2%
    Mar 18
    		$-0.40$-0.41+2.44%Beat+31.0%
    Dec 17
    		$-0.44$-0.52+15.38%Beat+15.4%
    Sep 17
    		$-0.54$-0.53-1.89%Miss-38.5%
    Jun 17
    		$-0.64$-0.57-12.28%Miss-
    Mar 17
    		$-0.58$-0.48-20.83%Miss-
    Dec 16
    		$-0.52$-0.45-15.56%Miss-
    Sep 16
    		$-0.39$-0.50+22.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-7.39EV/EBITDA-6.06x
    Price/FCF-9.25xFCF Yield-10.81%
    Profitability
    Profit Margin0.00%Operating Margin-609.00%
    ROE-73.00%ROIC-41.66%
    Financial Health
    Debt/Equity0.14xInterest Coverage-27.42x
    Current Ratio13.11xQuick Ratio13.03x
    Trading Statistics
    Beta0.94Avg Volume2.76M
    52-Week High$16.4452-Week Low$6.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.90
    SMA 20$10.20
    SMA 50$9.70
    SMA 200$9.96
    EMA 10$10.60
    EMA 20$10.29
    EMA 50$9.79
    EMA 200$9.70

    MACD

    Line: 0.41Signal: 0.43Hist: -0.02

    ADX

    ADX: 25.0+DI: 24.9-DI: 23.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down16.0
    PSAR$11.59

    Bollinger Bands

    Upper Band$12.05
    Lower Band$8.36
    %B Position3617%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    55.4

    Momentum Oscillators

    Stoch %K50.6
    Stoch %D59.8
    Williams %R-60.7
    ROC (10d)-1.5%
    Momentum-0.16
    CCI (20d)16.8
    MFI (14d)62.5

    Volatility Measures

    ATR (14d)$0.50(4.8%)
    StdDev (20d)0.92
    Hist Vol54.1%(High)

    Volume Flow

    VWAP$10.39
    OBV6.2M
    AD Line6.0M
    CMF (20d)-0.026

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio0.6x
    VWMA (20d)$10.39

    Pivot Points

    R3$11.42
    R2$11.19
    R1$10.78
    Pivot Point$10.55
    S1$10.14
    S2$9.91
    S3$9.50

    Advanced Oscillators

    TSI21.60
    Ultimate Osc43.6
    KST191.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$13.47M$10.79M$13.25M$14.54M$13.46M$10.70M$17.08M$15.43M$16.44M$14.77M$14.80M$15.08M
    Cost of Revenue$2.01M$1.33M$1.59M$1.77M$1.94M$1.26M$1.23M$1.56M$1.51M$1.33M$1.39M$1.38M
    Gross Profit$11.46M$9.46M$11.66M$12.77M$11.52M$9.44M$15.85M$13.86M$14.93M$13.45M$13.42M$13.70M
    Operating Expenses$93.57M$102.80M$81.42M$81.47M$79.16M$73.35M$66.43M$59.86M$58.52M$45.06M$33.47M$32.92M
    R&D$54.14M$66.21M$50.80M$52.36M$51.08M$42.86M$40.99M$37.05M$28.86M$20.73M$16.20M$15.02M
    SG&A$22.16M$20.01M$17.66M$16.02M$14.35M$16.35M$14.60M$12.23M$19.67M$14.15M$8.02M$8.58M
    Operating Income$-82,109,000$-93,340,000$-69,761,000$-68,698,000$-67,641,000$-63,917,000$-50,576,000$-45,998,000$-43,590,000$-31,617,000$-20,049,000$-19,214,000
    Interest Income$5.45M$6.05M$7.34M$3.73M$3.46M$3.83M$4.67M$5.65M$6.04M$3.92M$1.46M$1.21M
    Interest Expense$2.79M$2.78M$2.83M$3.00M$3.02M$2.98M$3.11M$3.22M$3.20M$32.00M$4.15M$-10,764,000
    Income Before Tax$-78,763,000$-88,612,000$-64,683,000$-69,418,000$-67,814,000$-64,053,000$-48,388,000$-36,493,000$-43,777,000$-64,848,000$-29,219,000$-516,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-78,763,000$-88,612,000$-64,654,000$-69,418,000$-67,814,000$-64,053,000$-48,388,000$-36,493,000$-43,777,000$-64,848,000$-29,220,000$-516,000
    EBITDA$-78,929,000$-89,221,000$-67,453,000$-68,318,000$-66,519,000$-62,478,000$-48,426,000$-37,342,000$-45,092,000$-33,881,000$-24,015,000$-9,530,000
    EBIT$-81,420,000$-91,885,000$-69,195,000$-70,145,000$-68,253,000$-64,895,000$-49,953,000$-38,922,000$-46,617,000$-36,769,000$-26,526,000$-12,492,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OCUL

    News

    Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story Builds

    Ocular Therapeutix (OCUL) is considered significantly undervalued, trading at US$10.78 against a narrative fair value of US$27.09. This undervaluation is largely due to the anticipated approval of AXPAXLI, a potential wet AMD product with superior dosing intervals, which could capture substantial market share and drive revenue growth. While the market currently assigns a high P/S ratio, the company's future relies heavily on Axpaxli's success and avoiding setbacks in trials or pricing pressure.

    Simply Wall Street•8/25/26•
    Bullish

    Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares

    An officer at Ocular Therapeutix (NASDAQ: OCUL), Sanjay Nayak, plans to sell 1,897 shares of common stock, valued at approximately $20,452.70, originating from restricted stock vesting. This is reported via a Rule 144 SEC filing. The filing also indicates that Nayak previously sold 1,858 shares on May 26, 2026, for $15,236.53.

    Stock Titan•8/24/26•
    Neutral

    Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale

    An officer at Ocular Therapeutix (NASDAQ: OCUL), Pravin Dugel, has filed a Form 144 indicating a planned sale of 21,649 shares of common stock, associated with restricted stock vesting on August 22, 2026. The proposed sale has an approximate market value of $233,185.71. Additionally, the filing reveals that Dugel sold 21,156 shares in the prior three months, generating aggregate proceeds of $173,513.05.

    Stock Titan•8/24/26•
    Somewhat-Bearish

    Ocular Therapeutix (NASDAQ: OCUL) insider plans 3,296-share sale

    Jeffrey S. Heier, an insider at Ocular Therapeutix (OCUL), plans to sell 3,296 common shares with an aggregate market value of $35,532.20. This sale is associated with restricted stock vesting under a registered plan and will be handled by Morgan Stanley Smith Barney LLC. The filing also indicates that Heier previously sold 3,018 common shares for $24,745.19 within the prior three months.

    Stock Titan•8/24/26•
    Neutral

    Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update

    Ocular Therapeutix (OCUL) saw its stock rise by 10.4% after reporting stronger-than-expected Q2 results and providing an update on its AXPAXLI Phase 3 trials. The company's pivotal retinal asset, AXPAXLI, remains on track for an FDA-aligned NDA submission in Q4 2026, bolstering investor confidence despite the company's reliance on this single asset and ongoing losses. The positive Week 52 SOL-1 topline data for AXPAXLI, highlighting its durability and safety, supports management's confidence in the regulatory pathway.

    Yahoo Finance•8/22/26•
    Bullish

    Frequently Asked Questions About OCUL

    Does OCUL pay dividends?
    Ocular Therapeutix Inc (OCUL) does not currently pay a regular dividend.
    What is OCUL's market cap?
    Ocular Therapeutix Inc (OCUL) has a market capitalization of $2.28B with a current stock price of $10.49.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In